We have assembled a team of industry leaders with operational experience across the life sciences spectrum to build the next generation of great life sciences companies.
Research & Development
IR & Communications
Sean Cao, PhD, MBA
Chief Executive Officer, Director
Prior to joining ABio-X, Sean was a Managing Director of CBC Group, co-founded and served as the CEO of Everest Medicines and was the VP of Global Business Development at Simcere Pharmaceutical Group. Sean was also the President and Board Director at Simcere America, a wholly owned subsidiary. Previously, Sean was the Senior Director of Alternative Partnerships, Evaluation & Expertise at Sanofi. Before Sanofi, Sean was an Associate at New Leaf Venture Partners, a healthcare VC firm. Earlier in his career, Sean worked in the pharmaceutical and diagnostic industries at Aventis and Johnson & Johnson. Sean currently serves as the Chairman of NiKang Therapeutics. He holds a PhD in Microbiology from the University of Virginia, an MBA with honor from the Wharton School of the University of Pennsylvania, and a Bachelor of Science in Microbiology from Nankai University, China.
Jenny has more than 20 years of financial experience in large multinational companies including Siemens, Tetra Pak, Stanley and Macdermid. She is a Certified Management Accountant and has a Senior Accountant title. Jenny graduated from Shanghai University of Finance & Economics with a Master’s Degree in Economics and Bachelor’s Degree in Accounting.
Eric Fink, MS
Chief Operating Officer
Over the past 20+ years, Eric has built and led multi-faceted Commercial, HR, and G&A organizations that met the needs of several diverse, fast-growing global biotechnology and pharmaceutical companies. Prior to ABio-X, Eric was EVP, Chief Human Resources Officer for Freeline and Global Blood Therapeutics (GBT). Before GBT, Eric served in multiple progressive leadership roles with Jazz Pharmaceuticals and earlier in his career held various commercial roles of increasing responsibility at Bayer HealthCare and GlaxoSmithKline. Eric earned his MS in Organizational Leadership from Mercyhurst University and Bachelor of Science in Biology at Pennsylvania State University.
Eddy began his career in the public accounting space at a medium sized Boston regional firm focusing on preparing tax returns as well as assurance services for clients ranging from mom-and-pop shops to large multi-million-dollar software companies. After leaving the public accounting field, he spent multiple years in the private equity funded SaaS industry focusing on general ledger accounting as well as driving process improvement. Prior to joining ABio-X, Eddy led the finance department for a concrete subcontractor. He is a Licensed CPA in the state of Massachusetts. Eddy received his Bachelor’s Degree in Accounting and Finance and MBA in Accounting from Assumption University.
Cindy Liu, MBA, CPA
Cindy brings over 16 years of experience in accounting and finance to ABio-X. Cindy has extensive experience in financial reporting for early-stage biotechnology companies in compliance with the AICPA and PCAOB standards, pre and post to the initial public offerings. Most recently, Cindy led teams of consultants in CFGI, where she provided technical accounting and financial consulting assistance to various companies in the automotive and biotechnology sectors. Prior to joining CFGI, Cindy served as the Finance Director at NASDAQ’s digital media business line where she was responsible for overseeing the financial reporting, budgeting and long-range planning processes. Earlier in her career, Cindy held a range of financial accounting and auditing roles of increasing responsibility at Acushnet Company and Ernst & Young, LLP. Cindy is an MBA, holds a Business Management Certificate from the University of Pennsylvania and is a Certified Public Accountant in the Commonwealth of Massachusetts and a Chartered Global Management Accountant recognized by the AICPA.
Karly (Jiayu) Liu
Prior to joining ABio-X, Karly was a market analyst at a Boston-based law firm. Since joining ABio-X, Karly assists our member companies build their finance and procurement structures in the US. She also supports the audits and company financings. Karly received her Bachelor of Science in Economics and Business at Capital University of Economics and Business in China and graduated from Boston University with a Master of Science in Marketing Management.
Director, Lab Operations
Andres brings over 20 years of operations experience to ABio-X. Andres has extensive experience designing, building, and maintaining multiple labs. Prior to joining ABio-X, Andres was the Senior Manager, Lab Operations at Simcere Innovation, the cell and gene therapy arm of Simcere Pharmaceutical. There he reduced operational inefficiencies that resulted in a resource surplus. Recently, Andres oversaw lab operations at Triplet Therapeutics, Thermo Fisher Scientific, and VWR (part of Avantor). At his previous roles, he ensured efficiency in daily site operations, developed process improvements, and maintained lab safety. He began his career at America’s Catch, where he managed the operations department. Andres graduated from Universidad Santiago de Cali with a degree in Marine Biology and Business.
Human Resources Generalist
Francesca graduated from Bryant University in 2020 with a degree in Human Resources Management and Communications. She joins the ABio-X team from Sirtex Medical, where she spent 4.5 years in Human Resources, progressing to HR Generalist.
Tianze has a MS degree in Pharmaceutical Sciences from The University of Southern California and a BS degree in Clinical Nutrition from UC Davis. He was inspired to pursue a career in pharmaceuticals and life sciences after the emergence of COVID-19, striving to deliver cutting edge therapeutics to patients in need. Prior to working at ABio-X, Tianze was an intern at CBC Group where he was responsible for conducting competitive intelligence research as well as financial analyses.
Vice President, Investor Relations & Communications
Before joining ABio-X, Jordyn was the Director of Investor Relations at CohBar, Inc., a NASDAQ listed clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While at CohBar, she led and built the investor relations, corporate communications, business development, and internal communication functions from an academic, founder run company to a mature publicly traded company. Previously, she was the Director of Investor Relations at NASDAQ listed Fluent, Inc. and OncoSec Medical. As the department head, she created successful investor relations and corporate communication functions, attracting top tier institutions and sell side research analysts. She started her career in investment banking at Rodman & Renshaw, where she assisted with raising in excess of $1 billion for a number of public and private companies utilizing various structures. Jordyn graduated Summa Cum Laude from DePaul University.
Joanna Wu, PhD, JD
Joanna has practiced law since 2003, with an initial focus on patent and FDA regulatory matters and later in other areas including corporate and technology transactions. She began her career with Ropes & Gray in Boston, followed by in-house experience in various medical device and biotechnology companies. She received her JD from University of California, Berkeley with a Certificate in Law and Technology, and she was on the editorial boards of the California Law Review and Berkeley Technology Law Journal. As a registered U.S. patent attorney, Joanna also has a technical background with a PhD in physiology from the University of Virginia and conducted research at the Lawrence Berkeley National Laboratory as a recipient of the Alexander Hollaender Distinguished Postdoctoral Fellowship from the U.S. Department of Energy.
Siyuan Xu, PhD
Director, Business Development
Prior to joining ABio-X, Siyuan led business development at VISEN Pharmaceutical. During her tenure at VISEN, she built the strategic framework to enrich the company pipeline through BD&L and spearheaded the $150 million Series B fundraising. Earlier in her career, Siyuan worked as an investment professional at healthcare-focused venture funds. Siyuan earned her Bachelor of Science and PhD from Fudan University. During her academic years, she published six peer-reviewed papers as the first author and filed one patent.
Terry has more than 15 years of IT experience in large multinational companies. Previously, he was the Senior Infrastructure Engineer at LVMH Perfumes & Cosmetics (Shanghai) and has held roles of increasing responsibility at Water Technologies, Bosch, Matson Navigation, FedEx, and HSBC. Terry graduated from Shanghai Normal University with a Bachelor’s Degree in Information and Science.